FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808586119> ?p ?o ?g. }

• W2808586119 abstract "Background The treatment of neuropsychiatric systemic lupus erythematosus (NPSLE) is extremely challenging and only a few clinical trials have been performed to establish optimal management. Objectives To describe the therapeutic approach and the short-term outcome of a multi-centre cohort of patients with NPSLE, enrolled at the time of the first NP event. Methods This is a retrospective cohort study. All NP events were defined according to American College of Rheumatology (ACR) case definition and divided into 3 clusters: central/diffuse (C/D), central/focal (C/F) and peripheral (P). A validated attribution algorithm was used to determine the attribution of all NP events. Demographic variables, global SLE disease activity Index 2000 (SLEDAI-2K), cumulative organ damage (SLICC/ACR Damage Index (SDI)) and treatment adopted for NP manifestations were collected. The clinical outcome of all NP events was determined by a physician-completed seven-point Likert scale (1=patient demise, 2=much worse, 3=worse, 4=no change, 5=improved, 6=much improved, 7=resolved). The relationship between the variables of interest and the outcome was analysed by crude and adjusted logistic models and reported as Odds Ratio (OR) and 95% confidence intervals (95% CI). Results 461 SLE patients with at least one NP event were included. 91.8% of patients were female, mean (SD) age 35.4 (13.6) years. 19.7% (91) of events were observed at diagnosis of SLE, 13.4% (62) before and 66.8% (308) after the diagnosis. 111 events (24.1%) were C/F, 286 (62%) C/D and 64 (13.9%) P. 198 (42.95%) of all NP events were attributed to SLE. The overall probability of immunosuppressive therapy was 28.4% (95% CI 24.3–32.8), 38.7% (95% CI 29.6–48.5) in C/F, 21.3% (95%CI 16.7–26.5) in C/D and 42.2% (95%CI 16.7–26.5) in P manifestations. The probability of immunosuppressive therapy was 47.9% (95% CI 40.8–55.2) in attributed events. The one-year outcome was available in 355 patients. Physician assessment indicated resolution (76 patients) or improvement (150 patients) in 49% (226/461) of cases. The crude and adjusted OR of attributed NP events and immunosuppressants on a favourable outcome is illustrated in Figure 1. The multivariable logistic regression analysis was done adjusting for age at diagnosis of SLE [OR 0.96, 0.94–0.98] p=0.001, female gender [OR 0.97, 0.33–2.7] p=0.959, SDI [0.85, 0.68–1.08] p=0.202, SLEDAI-2K [1.06, 1.01–1.11] p=0.008 and type of event (F/C [REF], C/D [0.37, 0.16–0.83] p=0.016, P [0.54, 0.21–1.42] p=0.215). Conclusions In our study, the therapeutic immunosuppressive approach was mostly used in attributed, C/F and P manifestations. In patients treated with immunosuppressants, the favourable outcome was lower in C/D phenotype. Disclosure of Interest None declared" @default.
• W2808586119 created "2018-06-21" @default.
• W2808586119 creator A5006082336 @default.
• W2808586119 creator A5010769181 @default.
• W2808586119 creator A5013492063 @default.
• W2808586119 creator A5013612547 @default.
• W2808586119 creator A5029683989 @default.
• W2808586119 creator A5029760845 @default.
• W2808586119 creator A5032266570 @default.
• W2808586119 creator A5034748610 @default.
• W2808586119 creator A5037295594 @default.
• W2808586119 creator A5038161485 @default.
• W2808586119 creator A5049244075 @default.
• W2808586119 creator A5051526168 @default.
• W2808586119 creator A5057605100 @default.
• W2808586119 creator A5059602308 @default.
• W2808586119 creator A5064303070 @default.
• W2808586119 creator A5069120603 @default.
• W2808586119 creator A5069264274 @default.
• W2808586119 creator A5069264564 @default.
• W2808586119 creator A5073480338 @default.
• W2808586119 creator A5076106222 @default.
• W2808586119 creator A5079447134 @default.
• W2808586119 creator A5084450056 @default.
• W2808586119 creator A5086941743 @default.
• W2808586119 creator A5088481433 @default.
• W2808586119 creator A5090580998 @default.
• W2808586119 date "2018-06-01" @default.
• W2808586119 modified "2023-10-16" @default.
• W2808586119 title "AB0503 Therapeutic strategy and short-term outcome in neuropsychiatric systemic lupus erythematosus" @default.
• W2808586119 doi "https://doi.org/10.1136/annrheumdis-2018-eular.6854" @default.
• W2808586119 hasPublicationYear "2018" @default.
• W2808586119 type Work @default.
• W2808586119 sameAs 2808586119 @default.
• W2808586119 citedByCount "0" @default.
• W2808586119 crossrefType "proceedings-article" @default.
• W2808586119 hasAuthorship W2808586119A5006082336 @default.
• W2808586119 hasAuthorship W2808586119A5010769181 @default.
• W2808586119 hasAuthorship W2808586119A5013492063 @default.
• W2808586119 hasAuthorship W2808586119A5013612547 @default.
• W2808586119 hasAuthorship W2808586119A5029683989 @default.
• W2808586119 hasAuthorship W2808586119A5029760845 @default.
• W2808586119 hasAuthorship W2808586119A5032266570 @default.
• W2808586119 hasAuthorship W2808586119A5034748610 @default.
• W2808586119 hasAuthorship W2808586119A5037295594 @default.
• W2808586119 hasAuthorship W2808586119A5038161485 @default.
• W2808586119 hasAuthorship W2808586119A5049244075 @default.
• W2808586119 hasAuthorship W2808586119A5051526168 @default.
• W2808586119 hasAuthorship W2808586119A5057605100 @default.
• W2808586119 hasAuthorship W2808586119A5059602308 @default.
• W2808586119 hasAuthorship W2808586119A5064303070 @default.
• W2808586119 hasAuthorship W2808586119A5069120603 @default.
• W2808586119 hasAuthorship W2808586119A5069264274 @default.
• W2808586119 hasAuthorship W2808586119A5069264564 @default.
• W2808586119 hasAuthorship W2808586119A5073480338 @default.
• W2808586119 hasAuthorship W2808586119A5076106222 @default.
• W2808586119 hasAuthorship W2808586119A5079447134 @default.
• W2808586119 hasAuthorship W2808586119A5084450056 @default.
• W2808586119 hasAuthorship W2808586119A5086941743 @default.
• W2808586119 hasAuthorship W2808586119A5088481433 @default.
• W2808586119 hasAuthorship W2808586119A5090580998 @default.
• W2808586119 hasBestOaLocation W28085861191 @default.
• W2808586119 hasConcept C126322002 @default.
• W2808586119 hasConcept C151956035 @default.
• W2808586119 hasConcept C156957248 @default.
• W2808586119 hasConcept C167135981 @default.
• W2808586119 hasConcept C198451711 @default.
• W2808586119 hasConcept C2776912625 @default.
• W2808586119 hasConcept C2779134260 @default.
• W2808586119 hasConcept C44249647 @default.
• W2808586119 hasConcept C71924100 @default.
• W2808586119 hasConcept C72563966 @default.
• W2808586119 hasConceptScore W2808586119C126322002 @default.
• W2808586119 hasConceptScore W2808586119C151956035 @default.
• W2808586119 hasConceptScore W2808586119C156957248 @default.
• W2808586119 hasConceptScore W2808586119C167135981 @default.
• W2808586119 hasConceptScore W2808586119C198451711 @default.
• W2808586119 hasConceptScore W2808586119C2776912625 @default.
• W2808586119 hasConceptScore W2808586119C2779134260 @default.
• W2808586119 hasConceptScore W2808586119C44249647 @default.
• W2808586119 hasConceptScore W2808586119C71924100 @default.
• W2808586119 hasConceptScore W2808586119C72563966 @default.
• W2808586119 hasLocation W28085861191 @default.
• W2808586119 hasOpenAccess W2808586119 @default.
• W2808586119 hasPrimaryLocation W28085861191 @default.
• W2808586119 hasRelatedWork W1967214746 @default.
• W2808586119 hasRelatedWork W2057873010 @default.
• W2808586119 hasRelatedWork W2315332968 @default.
• W2808586119 hasRelatedWork W2323482372 @default.
• W2808586119 hasRelatedWork W2411574989 @default.
• W2808586119 hasRelatedWork W2416930592 @default.
• W2808586119 hasRelatedWork W2574633469 @default.
• W2808586119 hasRelatedWork W2582740294 @default.
• W2808586119 hasRelatedWork W2591152909 @default.
• W2808586119 hasRelatedWork W2791924560 @default.
• W2808586119 hasRelatedWork W2912829463 @default.
• W2808586119 hasRelatedWork W2913154661 @default.
• W2808586119 hasRelatedWork W2936737119 @default.
• W2808586119 hasRelatedWork W2950112113 @default.
• W2808586119 hasRelatedWork W3004033164 @default.

• next